Therapeutic time window important factor for cord blood cell transplantation after stoke

October 1, 2012

A research team from Germany has found that optimal benefit and functional improvement for ischemic stroke results when human umbilical cord blood mononuclear cells (hUCB MNCs) are transplanted into rat stroke models within 72 hours of the stroke. Their study is published in the current issue of Cell Transplantation (21:6), now freely available on-line.

" is one of the most frequent causes of death and the most common reason for permanent disabilities in adults in industrialized nations," said Dr. Johannes Boltze, study corresponding-author from the University of Leipzig. "Despite recent research, treatment opportunities are limited and the only approved therapy to date must be administered within a narrow four and a half hour ."

According to the authors there is a "strong demand for alternative strategies," and among those most recently studied is using neonatal or . Their study investigates the time-dependent efficacy of hUCB MNCs following experimental brain ischemia in rats. The emphasis of their study was exploring factors that impact on Cell Transplantation to derive the best outcomes, such as determining an appropriate transplantation time point, or window of opportunity.

The researchers transplanted hUCB MNCs into test animals at various time intervals following stroke, at four hours, 24 hours, 72 hours, 120 hours and at 14 days.

"Our results demonstrated that transplantation within a 72 hour time window resulted in an early improvement in functional recovery," said Dr. Boltze.

"The failure to induce sustained functional recovery, lesion reduction, and limitation of glial scaring in animals treated at 120 hours indicates the 72 hour time window as efficient for cell application."

The authors noted that administration of hUCB MNCs within the 72 hour window resulted not only in but also a reduction in and in diminished glial scaring demonstrating the importance of this factor on the impact of umbilical cord blood Cell Transplantation. Later transplantation, at 14 days, showed no benefit.

"Our study shows that hUCB MNCs are a promising tool for acute stroke treatment, but require a comparatively early intervention in the subacute phase of ," concluded the authors.

"This research adds to a growing body of evidence supporting specific early time periods for repair of the brain, spinal cord, heart and other organs following acute injury and is very important in the development of regenerative therapies" said Dr. Paul R. Sanberg, Distinguished Professor of Neurosurgery and Brain Repair at the University of South Florida.

Explore further: Study finds cryopreserved endothelial progenitor cells phenotypically identical to non-frozen

More information: Boltze, J.; Schmidt, U. R.; Reich, D. M.; Kranz, A.; Reymann, K. G.; Strassburger, M.; Lobsien, D.; Wagner, D.-C.; Förschler, A.; Schäbitz, W.-R. Determination of the Therapeutic Time Window for Human Umbilical Cord Blood Mononuclear Cell Transplantation Following Experimental Stroke in Rats. Cell Transplant. 21(6):1199-1211; 2012. http://www.ingentaconnect.com/content/cog/ct/

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.